Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 30, 2023 17:00 ET
|
Pyxis Oncology
BOSTON, June 30, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers,...
Pyxis Oncology Advances PYX-106 and PYX-201 Clinical Programs
May 30, 2023 08:30 ET
|
Pyxis Oncology
First subject dosed in Phase 1 trial of PYX-106, a fully human immunotherapy antibody candidate Second dose level initiated in Phase 1 trial of PYX-201, an antibody-drug conjugate (ADC)...
Pyxis Oncology to Acquire Apexigen
May 24, 2023 06:45 ET
|
Pyxis Oncology
Pyxis Oncology positioned at forefront of Antibody-Drug Conjugate (ADC) development Commercially and clinically validated APXiMAB platform for antibody generation complements FACT ADC toolkit of...
Pyxis Oncology Reports Financial Results for the First Quarter 2023 and Provides Corporate Update
May 11, 2023 07:00 ET
|
Pyxis Oncology
Orphan Drug Designation received for PYX-201 in pancreatic cancer Preliminary data from two Phase 1 trials anticipated late 2023 to early 2024 Strong balance sheet with $150.8 million in cash...
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 31, 2023 17:00 ET
|
Pyxis Oncology
CAMBRIDGE, Mass., March 31, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat...
Pyxis Oncology Reports Financial Results for the Fiscal Year Ended December 31, 2022, and Provides Corporate Update
March 22, 2023 06:45 ET
|
Pyxis Oncology
Preliminary data from two Phase 1 trials anticipated late 2023 to early 2024 First subject dosed in Phase 1 trial of PYX-201; clinical sites being activated and patient screening underway in Phase 1...
Pyxis Oncology Announces Dosing of First Subject in Phase 1 Trial of PYX-201, a Novel ADC for Solid Tumors
March 16, 2023 07:30 ET
|
Pyxis Oncology
Milestone marks transition of Pyxis Oncology to a clinical-stage company Preliminary data anticipated in early 2024 CAMBRIDGE, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc....
Pyxis Oncology to Participate in the Virtual 2023 SVB Securities Global Biopharma Conference
February 13, 2023 08:00 ET
|
Pyxis Oncology
CAMBRIDGE, Mass., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next-generation therapeutics to target difficult-to-treat...
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 23, 2022 16:45 ET
|
Pyxis Oncology
CAMBRIDGE, Mass., Dec. 23, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next-generation therapeutics to target difficult-to-treat...
Pyxis Oncology Announces FDA Clearance of Two IND Applications
December 01, 2022 06:45 ET
|
Pyxis Oncology
FDA grants IND clearances of PYX-201, a novel antibody-drug conjugate (ADC) product candidate, and PYX-106, an immunotherapy product candidate Phase 1 clinical trials of PYX-201 and PYX-106 will...